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The influenza C virus (INF-C) hemagglutinin recognizes 9-0-acetyl-N-acetylneuraminic acid. The same protein contains the receptor-destroying enzyme (RDE), which is a 9-0-acetyl-esterase. The RDE was inactivated by the serine esterase inhibitor diisopropyl fluorophosphate (DFP). [3H]DFP-labeling localized the active site to the heavy chain of the glycoprotein. DFP did not alter the hemagglutination or fusion properties of the protein, but markedly decreased infectivity of the virus, demonstrating that the RDE is important for primary infection. Finally, DFP-treated INF-C
bound specifically and irreversibly to cells expressing 9-0-acetylated sialic acids. This provides a probe for a molecule that was hitherto very difficult to study.
SIALIC ACIDS (NEURAMINIC ACIDS)
can be O-acetylated at positions 4, 7, 8, or 9. We and others have demonstrated that these modifications are developmentally regulated (1-3), and that the addition of a single O-acetyl group can markedly affect the biological properties of the parent molecule (4-6). The biochemical study of O-acetylation of sialic acids in biological systems is fraught with many problems, especially loss and migration of O-acetyl groups during analysis (7). Since 9-0-acetyl-N-acetylneuraminic acid (Neu5,9Ac2) is the preferred receptor for the hemagglutinin of influenza C (INF-C) (8) we reasoned that the virus could be used as a direct and specific probe for 9-0-acetylation. However, when INF-C is incubated with cells expressing Neu5,9Ac2, an esterase [called the receptor-destroying enzyme (RDE)] causes a rapid and marked decrease in amount of the O-acetylation (9). We therefore sought ways to selectively block the esterase activity. As shown in Fig. 1, 1 (Fig. 2) . This binding was completely blocked by bovine submaxillary mucin (which is rich in Neu5,9Ac2) (Fig. 2) but not by an equivalent amount of bovine serum albumin. Thus, DFP-treated biotinylated INF-C is a specific probe for the presence of 9-0-acetylated sialic acids on cell surfaces.
These results also suggest that, although the hemagglutination and RDE activities of INF-C are both contained in the same glycoprotein and recognize the same structure (Neu5,9Ac2), they do not share the same binding site. To confirm this, we studied the hemagglutination properties of the treated virus. Hemagglutination activity was not blocked by DFP-treatment of INF-C (Fig.  3) . When the cells were warmed to 22?C, esterase activity caused the predicted loss of hemagglutination in the controls and the PMSF-treated sample. However, hemagglutination was preserved in the DFP-treated sample, and persisted for several days at 4?C. Thus, the binding of DFP to the serine active site of the esterase did not block the hemagglutination function; indeed, it made it stable rather than rapidly reversible.
To has an approximate molecular mass (Mr) of 82,000 (82K), and is derived by tryptic cleavage from a precursor (gpl) of approximately 105K (11) . GpII is composed of two disulfide-bonded subunits, gp65 (HA I), and gp3O (HA II). Under nonreducing conditions the major [3H]DFP-labeled peptide had an Mr of 89K (corresponding to gpII) (Fig. 4) . In the presence of a reducing agent, the size of the peptide shifted to 63K (corresponding to gp65). There was a minor band of 113K prior to reduction, and a less distinct band at 92K after reduction, which may represent a small amount of gpI. The gp3O band was not labeled, thus localizing the DFP binding site to gp65 (HAI).
Review of previously described serine protease and esterase active sites indicates that a Gly-X-Ser-X-Gly sequence is consistently found, presumably because of a common origin from a primordial precursor (12, 13). Upon examination of complementary DNA-derived amino acid sequences of the INF-C glycoprotein from two independent isolates ( By means of chromosomal walking techniques, the bcl-2 gene has recently been cloned and sequenced (3, 4) . The predicted products of human bcl-2 appear to be 26-kD (bcl-2-o) and 22-kD (bcl-2-f) proteins that (i) differ in their carboxyl termini as a result of alternative splice site selection; (ii) lack transmembrane, leader, or kinase domains; and (iii) share no significant homology with other proteins whose sequences are known (4). In all lymphomas with t(14q32;18q21) thus far examined, the rearranged bcl-2 gene is expressed at high levels and shows no evidence of gross alterations in its coding sequences (4, 5). Hence, aberrant expression of the bcl-2 gene, rather than an abnormal gene product, most likely accounts for any selective growth advantage that the t(14q32;18q21) may impart.
Given the possibility that expression of the bcl-2 gene may contribute to the altered growth characteristics of malignant lymphocytes harboring a t(14;18), we wondered whether expression of this gene occurs during normal lymphocyte proliferation. Several proto-oncogenes, including c-myc, become expressed in normal lymphocytes after stimulation with appropriate mitogens (6, 7). We therefore sought to determine whether the bcl-2 gene is expressed in these cells. Though oncogenic activity has yet to be demonstrated for bcl-2, we henceforth refer to the normal form of this gene as a proto-oncogene. Figure IA shows Northern blot data derived from human peripheral blood lymphocytes (PBL) that had been stimulated for various times with the mitogenic lectin phytohemagglutinin (PHA). Because levels of ribosomal RNA (rRNA) increase in PBL after stimulation with PHA, we compared equal amounts of total cellular RNA rather than RNA from equal numbers of cells. Accumulation of 8.5-and 5.5-kb mRNAs for bcd-2-a. and of a less abundant 3.5-kb mRNA for bcl-2-f rose from undetectable to maximal levels within 6 to 14 hours after stimulation of PBL with PHA. These three mature transcripts result from alternative polyadenylation and splice site selections
